Ira A. Oliff

3.7k total citations · 1 hit paper
12 papers, 1.7k citations indexed

About

Ira A. Oliff is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ira A. Oliff has authored 12 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Immunology. Recurrent topics in Ira A. Oliff's work include HER2/EGFR in Cancer Research (3 papers), Acute Myeloid Leukemia Research (2 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). Ira A. Oliff is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Acute Myeloid Leukemia Research (2 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). Ira A. Oliff collaborates with scholars based in United States, Sweden and Germany. Ira A. Oliff's co-authors include Abderrahim Fandi, James A. Reeves, Steven D. Averbuch, Vincent A. Miller, Michael Wolf, Joan H. Schiller, Ronald B. Natale, Christian Manegold, Rafael Rosell and John Grous and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Ira A. Oliff

12 papers receiving 1.6k citations

Hit Papers

Gefitinib in Combination With Paclitaxel and Carboplatin ... 2004 2026 2011 2018 2004 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
    2004 1.4k citations Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology profile →

Peers

Ira A. Oliff
H. Spiridonidis United States
L. Fehrenbacher United States
Xiuyu Julie Cong United States
V. A. Miller United States
Fabrice Branle Switzerland
Jaromı́r Roubec Czechia
Daniel T. Milton United States
V. Damiano Italy
G Pomatico Italy
Didier Verhoeven Belgium
H. Spiridonidis United States
Ira A. Oliff
Citations per year, relative to Ira A. Oliff Ira A. Oliff (= 1×) peers H. Spiridonidis

Countries citing papers authored by Ira A. Oliff

Since Specialization
Citations

This map shows the geographic impact of Ira A. Oliff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ira A. Oliff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ira A. Oliff more than expected).

Fields of papers citing papers by Ira A. Oliff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ira A. Oliff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ira A. Oliff. The network helps show where Ira A. Oliff may publish in the future.

Co-authorship network of co-authors of Ira A. Oliff

This figure shows the co-authorship network connecting the top 25 collaborators of Ira A. Oliff. A scholar is included among the top collaborators of Ira A. Oliff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ira A. Oliff. Ira A. Oliff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Oliff, Ira A., et al.. (2022). Isolated Enteric Myeloid Sarcoma as a Rare Etiology of Small Bowel Obstruction in a Young Female Patient. Gastroenterology Research. 15(1). 39–46. 2 indexed citations
2.
Chung, Vincent, Jaime R. Merchan, Allyson J. Ocean, et al.. (2018). RX 3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer–Preliminary results of stage II of the phase Ia/IIb study.. Journal of Clinical Oncology. 36(4_suppl). 396–396. 1 indexed citations
3.
Saba, Raya, et al.. (2017). Buccal Epithelium, Cigarette Smoking, and Lung Cancer: Review of the Literature. Oncology. 93(6). 347–353. 7 indexed citations
4.
Yardley, Denise A., Robert Weaver, Michelle Melisko, et al.. (2015). EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer. Journal of Clinical Oncology. 33(14). 1609–1619. 145 indexed citations
5.
Yardley, DA, MN Saleh, Andres Forero, et al.. (2012). Abstract P6-10-01: A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study. Cancer Research. 72(24_Supplement). P6–10. 12 indexed citations
6.
Kindler, Hedy L., Howard A. Burris, Alan B. Sandler, & Ira A. Oliff. (2008). A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Investigational New Drugs. 27(1). 75–81. 62 indexed citations
7.
Jensen, Markus, Andreas Engert, Florian Weißinger, et al.. (2007). Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Investigational New Drugs. 26(2). 139–149. 22 indexed citations
8.
Herbst, Roy S., Giuseppe Giaccone, Joan H. Schiller, et al.. (2004). Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2. Journal of Clinical Oncology. 22(5). 785–794. 1374 indexed citations breakdown →
9.
10.
Oliff, Ira A. & Carolyn C. Compton. (2000). Case 7-2000. New England Journal of Medicine. 342(10). 722–728. 4 indexed citations
11.
Radomska, Hanna S., Anne B. Satterthwaite, Timothy C. Burn, Ira A. Oliff, & Daniel G. Tenen. (1998). Multiple control elements are required for expression of the human CD34 gene. Gene. 222(2). 305–318. 26 indexed citations
12.
Oliff, Allen, et al.. (1984). Isolation of immortal cell lines from the first stage of murine leukemia virus-induced leukemia.. Proceedings of the National Academy of Sciences. 81(17). 5464–5467. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Spiridonidis Breakdown of academic impact, for papers by L. Fehrenbacher Breakdown of academic impact, for papers by Xiuyu Julie Cong Breakdown of academic impact, for papers by V. A. Miller Breakdown of academic impact, for papers by Fabrice Branle Breakdown of academic impact, for papers by Jaromı́r Roubec Breakdown of academic impact, for papers by Daniel T. Milton Breakdown of academic impact, for papers by V. Damiano Breakdown of academic impact, for papers by G Pomatico Breakdown of academic impact, for papers by Didier Verhoeven
Rankless by CCL
2026